Ratings SMAIO

Equities

ALSMA

FR0014005I80

Market Closed - Euronext Paris Other stock markets 12:30:10 07/06/2024 pm IST			5-day change	1st Jan Change
3.85 ^EUR	0.00%		+0.79%	+25.00%

23/01	S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023	CI
2023	S.M.A.I.O S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company is in a robust financial situation considering its net cash and margin position.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's enterprise value to sales, at 3.06 times its current sales, is high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SMAIO	+25.00%	21.76M	-
ELI LILLY AND COMPANY	+45.82%	765B	C+
NOVO NORDISK A/S	+40.95%	632B	B
JOHNSON & JOHNSON	-6.16%	354B	C+
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	299B	C+
ASTRAZENECA PLC	+18.45%	248B	B+
ROCHE HOLDING AG	-0.78%	219B	A+
NOVARTIS AG	+11.88%	216B	B-
AMGEN INC.	+5.90%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes